Home > Insider Trading > Filing (0001209191-15-016079)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576263	Mirati Therapeutics Inc.	MRTX	Pharmaceutical Preparations (2834)	462693615

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1599324	Jamie Christensen	C/O Mirati Therapeutics, Inc. 9363 Towne Centre Drive, Suite 200 San Diego CA 92121	Svp & Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2015-02-17	1,250	$22.29	1,250	No	4	S	Direct
Common Stock	Acquisiton	2015-02-17	400	$8.50	1,650	No	4	M	Direct
Common Stock	Disposition	2015-02-17	400	$23.10	1,250	No	4	S	Direct
Common Stock	Acquisiton	2015-02-19	3,100	$8.50	4,350	No	4	M	Direct
Common Stock	Disposition	2015-02-19	3,100	$23.02	1,250	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2015-02-17	400	$0.00	400	$8.50
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2015-02-19	3,100	$0.00	3,100	$8.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
27,100		2020-07-16	No	4	M	Direct
24,000		2020-07-16	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.0756, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (July 17, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.